BeOne Medicines Ltd.
ONCNasdaq
$312.02
↓ -1.7%Jul 17 close · end-of-day
Price
1Y↑ +11.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$469.6B
Enterprise Value
$465.9B
P/E
917.7
P/S
81.8
P/B
98.6
EV/EBITDA
557.3
PEG
—
FCF Yield
0.2%
Dividend Yield
—
Revenue (TTM)
$5.7B
Net Income (TTM)
$513.0M
Free Cash Flow (TTM)
$1.1B
Gross Margin
88.3%
Operating Margin
11.9%
Net Margin
8.9%
ROE
10.8%
ROIC
51.3%
Debt / Equity
0.2
Net Cash
$3.7B
Return 1Y
+7.5%
Company profile
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma. Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC)
- CEO
- John V. Oyler
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 9,000
- Website
- beigene.com
Management & directors
- Oyler JohnChief Executive Officer
- Lee Chan HenrySVP, General Counsel
- Wang LaiPresident, Global Head of R&D
- Wu XiaobinPresident and COO
- Ball Titus B.Principal Accounting Officer
- Rosenberg AaronChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
ONC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.5B↑ +35.5%
Diluted EPS$0.15—
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $308.9M | $1.2B | $1.4B | $2.5B | $3.8B | $5.3B |
| Gross profit | — | $1.0B | $1.1B | $2.1B | $3.2B | $4.7B |
| Operating income | -$1.7B | -$1.4B | -$1.8B | -$1.2B | -$568.2M | $447.1M |
| Net income | -$1.6B | -$1.5B | -$2.0B | -$881.7M | -$644.8M | $286.9M |
| Diluted EPS | -$1.50 | -$1.21 | -$1.49 | -$0.65 | -$0.47 | $0.19 |
| Operating cash flow | -$1.3B | -$1.3B | -$1.5B | -$1.2B | -$140.6M | $1.1B |
| Free cash flow | -$1.4B | -$1.6B | -$1.8B | -$1.7B | -$633.3M | $941.7M |
| Gross margin | — | 86.0% | 79.8% | 84.5% | 84.4% | 87.5% |
| Operating margin | -536.7% | -122.3% | -126.4% | -49.1% | -14.9% | 8.4% |
| Net margin | -526.1% | -123.9% | -141.5% | -35.9% | -16.9% | 5.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $929.2M | $1.0B | $1.1B | $1.1B | $1.3B | $1.4B | $1.5B | $1.5B |
| Gross profit | $791.0M | $831.1M | $967.3M | $952.3M | $1.2B | $1.2B | $1.4B | $1.3B |
| Operating income | -$107.2M | -$120.3M | -$79.4M | $11.1M | $87.9M | $163.1M | $185.0M | $249.9M |
| Net income | -$120.4M | -$121.3M | -$151.9M | $1.3M | $94.3M | $124.8M | $66.5M | $227.4M |
| Diluted EPS | -$0.09 | -$0.09 | -$0.10 | $0.00 | $0.06 | $0.08 | $0.05 | $0.15 |
| Operating cash flow | -$95.6M | $188.4M | $75.2M | $44.1M | $263.6M | $402.6M | $417.3M | $201.3M |
| Free cash flow | -$205.5M | $54.7M | -$17.3M | -$12.3M | $219.8M | $354.5M | $379.8M | $160.5M |
| Gross margin | 85.1% | 83.0% | 85.8% | 85.2% | 87.5% | 86.1% | 90.5% | 89.0% |
| Operating margin | -11.5% | -12.0% | -7.0% | 1.0% | 6.7% | 11.5% | 12.4% | 16.5% |
| Net margin | -13.0% | -12.1% | -13.5% | 0.1% | 7.2% | 8.8% | 4.4% | 15.0% |
Company news
Jul 17, 2026
Jun 30, 2026
- 20d agoIs BeOne Medicines AG (ONC) Stock Positioned for Growth After Encouraging ASCO Cancer Data?finance.yahoo.com
- 20d agoExchange-Traded Funds Mixed, Equity Futures Lower Pre-Bell Ahead of Key Economic Reportsfinance.yahoo.com
- 20d agoBeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphomafinance.yahoo.com
Jun 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-17 | OYLER JOHN· Chief Executive Officer | Sale | 35,829 | $312.17 | $11.2M | filing |
| 2026-07-17 | OYLER JOHN· Chief Executive Officer | Option exercise | 64,628 | $119.96 | $7.8M | filing |
| 2026-07-17 | OYLER JOHN· Chief Executive Officer | Sale | 14,915 | $313.19 | $4.7M | filing |
| 2026-07-17 | OYLER JOHN· Chief Executive Officer | Sale | 5,543 | $311.42 | $1.7M | filing |
| 2026-07-17 | OYLER JOHN· Chief Executive Officer | Sale | 4,833 | $310.37 | $1.5M | filing |
| 2026-07-17 | OYLER JOHN· Chief Executive Officer | Sale | 1,440 | $305.20 | $439,485.84 | filing |
| 2026-07-17 | OYLER JOHN· Chief Executive Officer | Sale | 740 | $314.32 | $232,596.65 | filing |
| 2026-07-17 | OYLER JOHN· Chief Executive Officer | Sale | 680 | $309.05 | $210,156.79 | filing |
| 2026-07-17 | OYLER JOHN· Chief Executive Officer | Sale | 597 | $306.96 | $183,257.63 | filing |
| 2026-07-17 | OYLER JOHN· Chief Executive Officer | Sale | 51 | $315.06 | $16,068.18 | filing |
| 2026-07-16 | OYLER JOHN· Chief Executive Officer | Option exercise | 96,501 | $160.40 | $15.5M | filing |
| 2026-07-16 | OYLER JOHN· Chief Executive Officer | Sale | 42,798 | $317.79 | $13.6M | filing |
| 2026-07-16 | OYLER JOHN· Chief Executive Officer | Sale | 32,224 | $316.82 | $10.2M | filing |
| 2026-07-16 | OYLER JOHN· Chief Executive Officer | Option exercise | 70,096 | $119.96 | $8.4M | filing |
| 2026-07-16 | OYLER JOHN· Chief Executive Officer | Sale | 20,505 | $321.00 | $6.6M | filing |
| 2026-07-16 | OYLER JOHN· Chief Executive Officer | Sale | 19,752 | $316.00 | $6.2M | filing |
| 2026-07-16 | OYLER JOHN· Chief Executive Officer | Sale | 15,097 | $319.99 | $4.8M | filing |
| 2026-07-16 | OYLER JOHN· Chief Executive Officer | Sale | 13,109 | $321.61 | $4.2M | filing |
| 2026-07-16 | OYLER JOHN· Chief Executive Officer | Sale | 9,516 | $314.73 | $3.0M | filing |
| 2026-07-16 | OYLER JOHN· Chief Executive Officer | Sale | 6,402 | $318.55 | $2.0M | filing |
| 2026-07-16 | OYLER JOHN· Chief Executive Officer | Sale | 4,881 | $314.08 | $1.5M | filing |
| 2026-07-16 | OYLER JOHN· Chief Executive Officer | Sale | 1,560 | $322.71 | $503,423.86 | filing |
| 2026-07-16 | OYLER JOHN· Chief Executive Officer | Sale | 520 | $323.59 | $168,264.62 | filing |
| 2026-07-16 | OYLER JOHN· Chief Executive Officer | Sale | 233 | $311.98 | $72,691.34 | filing |
| 2026-07-15 | OYLER JOHN· Chief Executive Officer | Sale | 48,657 | $312.86 | $15.2M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.